StockMarketWire.com - Motif Bio confirms the signing of a Phase III clinical trials agreement with Covance, a Contract Research Organisation (CRO) and subsidiary of Laboratory Corp. The trials are for iclaprim, a targeted spectrum antibiotic designed to be effective against multi-drug-resistant bacteria, including MRSA.

Covance will run two Phase III randomised, double blind, multicentre clinical trials with iclaprim.

The trials will evaluate the efficacy and safety of intravenous iclaprim versus intravenous vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI).

In addition to Covance's considerable experience running antibiotic trials, a key consideration for Motif in selecting Covance as its development partner, was the ability to leverage LabCorp's powerful patient data for these trials.






Story provided by StockMarketWire.com